Effect of Omega 3 fatty acids and vitamin E supplementation on symptoms of primary dysmenorrhea

Effect of Omega 3 fatty acids and vitamin E supplementation on symptoms of primary dysmenorrhea in resident students at Ahvaz Jundishapur University of Medical Sciences student accommodation: A randomized, single-blind, placebo-controlled clinical trial

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

IRCT

Registry ID

IRCT2014102519669N1

Enrollment

100

Registered

2014-12-17

Start date

2013-12-22

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

dysmenorrhoea. Primary dysmenorrhoea

Interventions

Intervention 1: Intervention group III: vitamin E, 200 units + Omega 3, 300 mg(180 docosahexaenoic acid acid mg +120 mg eicosapentaenoic acid), Manufacturing in Zahravi pharmaceutical company, daily,

Treatment - Drugs

Intervention group III: vitamin E, 200 units + Omega 3, 300 mg(180 docosahexaenoic acid acid mg +120 mg eicosapentaenoic acid), Manufacturing in Zahravi pharmaceutical company, daily, two days before

Intervention group II: Omega 3, 300 mg(180 docosahexaenoic acid acid mg +120 mg eicosapentaenoic acid), Manufacturing in Zahravi pharmaceutical company, daily, two days before and three days of menstr

Intervention group I:vitamin E, 200 units, Manufacturing in Zahravi pharmaceutical company, daily, two days before and three days of menstruation, two menstrual periods

Group IV: Placebo

Eligibility

Sex/Gender

Female

Age

18 Years to 30 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: People who have primary dysmenorrheal and use irregular NSAIDS and OCP. Exclusion criteria: Patients with secondary dysmenorrhea (endometriosis, adenomyosis, leiomyoma, uterine anomaly, Endometrial Polyps, ovarian cyst).

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Pain duration. Timepoint: at first and two months after intervention. Method of measurement: based on hours.	—

Secondary

Measure	Time frame
Pain intensity. Timepoint: At first and two months after intervention. Method of measurement: Based on the VAS pain intensity.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr. Sima Jafarirad

Ahvaz Jundishapur University of Medical Science

SJafari@ajums.ac.ir+98 61 3337 3858

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026